000			02792cam a2200349 a 4500
003			EG-GiCUC
005			20250223031438.0
008			160309s2015 ua f m 000 0 eng d
040			_aEG-GiCUC _beng _cEG-GiCUC
041	0		_aeng
049			_aDeposite
097			_aM.Sc
099			_aCai01.11.27.M.Sc.2015.Mi.S
100	0		_aMira Maher Sadia
245	1	0	_aSomatostatin receptor 2A expression in meningioma histopathological and immunohistochemical study / _cMira Maher Sadia ; Supervised Gina Assaad Assaad Nakhla , Ahmed Abdelmonem Soliman , Shady Elia Anis
246	1	5	_aتعبير مستقبل سوماتوستاتين 2أ فى اورام الاغشية السحائية: _bدراسة نسيجية مناعية
260			_aCairo : _bMira Maher Sadia , _c2015
300			_a82 P. ; _c25cm
502			_aThesis (M.Sc.) - Cairo University - Faculty of Medicine - Department of Pathology
520			_aMeningiomas are the most common among the primary central nervous system tumors. Schwannomas of the craniospinal axis and meningeal hemangiopericytomas are much less frequent tumors, however the distinction between certain histologic subtypes of meningioma and either of them can be challenging in some cases. Somatostatin receptors are highly expressed in meningioma and can be used as a good meningioma immunohistochemical marker. In addition, Somatostatin shows antiproliferative and antiangiogenic effects and can be used as targeted therapy. This study tested the immunohistochemical expression of SSTR2A in 35 cases of meningioma (16 grade I, 14 grade II and 5 grade III), 10 cases of intracranial schwannoma and 10 cases of hemangiopericytoma. The cases were retrieved as routinely processed paraffin blocks from the department of pathology, Kasr Alainy hospital, Cairo university and from a private laboratory. Positive immunostaining for SSTR2A was encountered in 89% of meningiomas, 0% of schwannomas and 0% of hemangiopericytomas (p value < 0.05). In meningiomas, all cases of grade I and grade II showed positive staining and only one out of five cases (20%) of grade III showed positive staining (p < 0.05). SSTR2A is a highly specific marker and can be used in the distinction between meningioma, particularly grade I and II, and schwannoma or hemangiopericytoma. It is also suggested that it can be used as a good prognostic marker for meningioma
530			_aIssued also as CD
653		4	_aHemangiopericytoma
653		4	_aMeningioma
653		4	_aSchwannoma
700	0		_aAhmed Abdelmonem Soliman , _eSupervisor
700	0		_aGina Assaad Assaad Nakhla , _eSupervisor
700	0		_aShady Elia Anis , _eSupervisor
856			_uhttp://172.23.153.220/th.pdf
905			_aNazla _eRevisor
905			_aSamia _eCataloger
942			_2ddc _cTH
999			_c55454 _d55454